Plain-English translation of NCT06199479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
After treatment for a brain tumor, sometimes imaging scans show changes that look like the tumor is growing back — but they might actually be caused by side effects of the treatment itself, not real tumor growth. This study is testing whether advanced MRI and CT scans can accurately tell the difference between true tumor progression and these treatment-related changes. Researchers will compare the imaging results with tissue samples taken during a biopsy to find out which imaging methods work best.
Right now, doctors sometimes struggle to know whether changes seen on imaging scans mean the tumor is truly coming back or if it's just a normal reaction to treatment. This confusion can lead to unnecessary worry or delay in treatment decisions. This study aims to find imaging tools that give doctors a clearer, more reliable answer.
You likely qualify if…
You likely don't qualify if…
You will have advanced MRI and CT imaging scans performed within 1–2 weeks before your planned biopsy, typically a few days before the procedure. These scans will include standard imaging plus special advanced techniques that help doctors see more detail about what's happening in your brain. The imaging results will then be compared with the tissue sample your doctor collects during your biopsy, so researchers can learn which imaging methods are most accurate at spotting real tumor growth.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~25 participants
Started
June 2024
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dawid Schellingerhout, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.